• FDA Approves Hibsago for Chronic HBV Infection

    FDA Approves Hibsago for Chronic HBV Infection
    Originally published by our sister publication Infectious Disease Special EditionBy Meaghan Lee CallaghanThe FDA has approved bepirovirsen (Hibsago, GSK) for the treatment of chronic hepatitis B virus (HBV) infection.The drug, a first-in-class antisense oligonucleotide, is approved for use in adult patients without cirrhosis who are receiving nucleoside/nucleotide analog reverse transcriptase inhibitor therapy, who have suppressed HBV DNA, and with HBV surface antigen (HBsAg) levels at or less t
  • Getting the Most Value Out of IV Software Products

    Getting the Most Value Out of IV Software Products
    By Karen BlumIn 2020, pharmacists with the Spaulding Rehabilitation Network purchased an IV solution software product to track training and activities modules related to IV sterile compounding. However, they soon discovered the program could be used for so much more outside the clean room.They launched the product initially in the clean room of their primary hospital, one of three hospitals and nursing homes in the Boston area that are part of Mass General Brigham. “The idea was to get rid of

Follow @newsl_pharmacy on Twitter!